In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 5, 1996, Pages 286-295

  Fridborg, Helena ^a   Nygren, Peter ^a   Dhar, Sumeer ^a   Csoka, Katalin ^a   Kristensen, Jörgen ^a   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cross resistance; Cytotoxicity assay; Drug development; Human cancer; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLYCOPROTEIN P; NAVELBINE; VINBLASTINE;

ARTICLE; BIOPSY; CELL CULTURE; DRUG RESISTANCE; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; QUALITY CONTROL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOPSY; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; QUALITY CONTROL; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0030223279     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Goldin A, Vendett JM, Macdonald JS, Muggia FM, Henney JE, Devita Jr VT. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 17: 129-142, 1981.
2. Weisenthal LM. Antineoplastic drug screening belongs in the laboratory, not in the clinic. J Natl Cancer Inst 84: 466-469, 1992.
3. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092, 1989.
4. Weinstein JN, Kohn KW, Grever MR, et al. Neural computing in cancer drug development: predicting mechanism of action. Science 258: 447-451, 1992.
5. Weisenthal LM. Predictive assays for drug and radiation resistance. In: Masters J, (ed.) Human cancer in primary culture, a handbook. Dordrecht: Kluwer Academic Publishers, The Netherlands, 103-147, 1991.
6. Nygren P, Fridborg H, Csoka K, et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 56: 715-720, 1994.
7. Goa KL, Faulds D. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 5: 200-234, 1994.
8. Binet S, Chaineau E, Fellous A, et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 46: 262-266, 1990.
9. Le Chavalier T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
10. Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP, Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol 16(Suppl 4): 15-20, 1989.
11. Maral R, Bourut C, Chenu E, Mathé G. Experimental anti-tumor activity of 5′-nor-anhydrovinblastine navelbine. Cancer Lett 22: 49-54, 1984.
12. Otter GM, Sirotnak FM. Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine. Cancer Chemother Pharmacol 33: 286-290, 1994.
13. Eghbali H. Phase II study of vinorelbine (Navelbine) in previously treated Hodgkin's disease and non-Hodgkin's lymphomas. In: Solal-Celigny P, (ed.) Navelbine (Vinorelbine). Update and new trends. Montrouge: John Libbey Eurotext Limited, 253-260, 1991.
14. Bruno S, Savignano R, Corrado C, et al. Vinorelbine (NVB): a new vinca alkaloid active in refractory/relapsed lymphomas. A phase II study. Proceedings of ASCO 13: 383 (abstract no. 1300), 1994.
15. Héron J-F, George MJ, Kerbrat P, et al. Phase II study of navelbine as second or third line treatment in advanced ovarian carcinoma. In: Solal-Celigny P, (ed.) Navelbine (vinorelbine). Update and new trends. Montrouge: John Libbey Eurotext Limited, 231-236, 1991.
16. Pinel MC, Pinon G, Goudier MJ, et al. Study of the combination vinorelbine-hexamethylmelamine (V-H) in advanced ovarian adenocarcinoma: preliminary results of a phase I-II study NHO-88, from the ARTAC multicentric ovarian carcinoma study group. In: Solal-Celigny P, (ed.) Navelbine (vinorelbine). Update and new trends. Montrouge: John Libbey Eurotext limited, 237-249, 1991.
17. Maral R, Bourut C, Chenu E, Mathé G. Experimental in vivo cross-resistance of vinca alkaloid drugs. Cancer Chemother Pharmacol 5: 197-199, 1981.
18. McClean S, Whelan RDH, Hosking LK, Hill BT. Expression of drug resistance in Chinese hamster ovary ICHO) cells following X-ray pre-treatment in vitro. Biochem Soc Trans 19: 278S, 1991.
19. Debal V, Morjani H, Millot JM, Angiboust JF, Gourdier B, Manfait M. Determination of vinorelbine (Navelbine) in tumour cells by high-performance liquid chromatography. J Chromatogr 581: 93-99, 1992.
20. Debal V, Allam N, Morjani H, et al. Characterisation of a navelbine-resistance bladder carcinoma cell line cross-resistant to taxoids. Br J Cancer 70: 1118-1125, 1994.
21. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that express P-glycoprotein. Cancer Res 46: 5125-5130, 1986.
22. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 51: 995-1002, 1991.
23. Mulcahy RT, Bailey HH, Gipp JJ. Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 34: 67-71, 1994.
24. Botling J, Liminga G, Larsson R, Nygren P, Nilsson K. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer 58: 269-274, 1994.
25. Mirski SEL, Gerlach JH, Cole SPC. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47: 2594-2598, 1987.
26. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
27. Danks MK, Yalowich JC, Beck WT. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297-1301, 1987.
28. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869, 1988.
29. Nygren P, Larsson R. Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes to the cytoplasmic free Ca2+ concentration. Biosci Rep 10: 231-237, 1990.
30. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177-185, 1992.
31. Csoka K, Larsson R, Tholander B, et al. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 54: 163-170, 1994.
32. Csoka K, Liliemark J, Larsson R, Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 22: 47-53, 1995.
33. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anti-cancer drug discovery screen. Drug Discovery Research 34: 91-109, 1995.
34. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 5: 817-820, 1994.
35. Burris HA, Fields S. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol 21: 14-20, 1994.
36. Boré P, Rahmani R, van Cantfort J, Focan C, Cano JP. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol 23: 247-251, 1989.
37. Canobbio L, Boccardo F, Guarneri D, et al. Phase II study of navelbine in advanced renal cell carcinoma. Eur J Cancer 27: 804-805, 1991.
38. Wilding G, Kirkwood J, Clamon G, et al. Phase II trial of Navelbine in metastatic renal cancer. Proceedings of ASCO 12: 253(abstract no. 798), 1993.
39. Tominaga T, Nomura Y, Furuse K, et al. Early phase II study of Navelbine (vinorelbine). Ann Oncol 3: 127(abstract no. 271), 1992.
40. Wu L, Smythe AM, Stinson SF, et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52: 3029-3034, 1992.
41. Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R. Anticancer drug characterization using a human cell-line panel representing defined types of drug resistance. Br J Cancer (in press), 1996.
42. Weisenthal LM, Dill P, Birkhofer M. Accurate identification of disease-specific activity of antineoplastic agents with an in vitro fresh tumor assay measuring killing of largely non-dividing cells. Proc Am Ass Cancer Res 32: 2280, 1991.
43. Larsson R, Fridborg H, Csoka K, et al. In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of hematological and solid tumors. Eur J Cancer 30A: 1022-1026, 1994.
44. Nygren P, Csoka K, Jonsson B, et al. The cytotoxic activity of Taxol in primary cultures of tumor cells from patients is partly mediated by Cremophor EL. Br J Cancer 71: 478-481, 1995.